The Multiple Myeloma Research Consortium Announces the Initiation of Phase I/II Study of Elotuzumab
News Jul 21, 2008
The Multiple Myeloma Research Consortium (MMRC) has announced the initiation of a Phase I/II study of elotuzumab (also known as Huluc63), a humanized anti-CS1 monoclonal IgG1 antibody administered intravenously, in combination with VELCADE® (bortezomib) for Injection for the treatment of relapsed multiple myeloma.
This study, sponsored by PDL BioPharma, Inc., and conducted at the following MMRC Member Institutions: the University of Michigan, Dana-Farber Cancer Institute, University of Chicago, Hackensack University Medical Center, and Roswell Park Cancer Institute, will evaluate the safety and efficacy of the combination in patients who have received one to three prior therapies.
“Elotuzumab is a novel antibody that hits a target – CS1 – known to be highly expressed on myeloma cells with a restricted expression on normal cells,” says Principal Investigator, Andrzej Jakubowiak, MD, PhD, Associate Professor, Hematology/Oncology at the University of Michigan. “Preclinical research suggests synergy between the antibody and Velcade, so we look forward to testing this promising new combination within the MMRC.”
“The MMRC is proud to partner with PDL BioPharma to move this exciting new combination into the clinic. The MMRC’s facilitation of this trial underscores our commitment to advancing clinical trials of novel compounds and combination approaches that show the most potential in effectively treating patients,” said Kathy Giusti, Founder and Chief Executive Officer of the MMRC, as well as a myeloma patient.